Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: betone who wrote (8)	6/29/2001 2:08:53 PM
From: $Mogul	Respond to of 276

Illumina Signs Genotyping Services Agreement With GlaxoSmithKline SNP Scoring Service to Leverage Illumina's BeadArray Platform Technology SAN DIEGO, Jun 29, 2001 (BW HealthWire) -- Illumina, Inc. announced today that it has signed a commercial agreement with GlaxoSmithKline (GSK) to provide single nucleotide polymorphism (SNP) genotyping services on a sample collection provided by GSK. Under the terms of the agreement, Illumina will use its BeadArray(TM) technology to "score," or determine the frequency of specified SNPs in the sample set. Further details were not disclosed. "We're pleased to begin working with GlaxoSmithKline, a global pharmaceutical firm and leader in employing new technologies to accelerate drug discovery," stated Jay Flatley, Illumina President and CEO. "Commercialization of our genetic analysis services business will drive the scale-up of genotyping assay development and help us refine BeadArray core technologies," added Flatley. Illumina (Nasdaq:ILMN; www.illumina.com) is developing next-generation tools that will permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology will provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals. Statements included in this press release that are not historical in nature may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include statements about Illumina's product introduction timeline or the Company's ability to further commercialize its genetic analysis services business or develop its core technologies. Any such forward-looking statements involve risks and uncertainties and reflect Illumina's judgment as of the date of this release. Actual events or results may differ from Illumina's expectations as a result of risks and uncertainties identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission, including those discussed in "Factors Affecting Our Operating Results" and elsewhere in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000 or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release and claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Contact: Illumina, Inc. Jay Flatley, 858/587-4290 Ext. 251 jflatley@illumina.com or William Craumer, 858/587-4290 Ext. 332 bcraumer@illumina.com